12/24/2023 0 Comments 2016 quicken home and business“Now that the FDA has cleared our IND, we look forward to initiating our KT-413 Phase 1 study in patients with relapsed/refractory B cell lymphomas, including MYD88 mutant DLBCL,” said Nello Mainolfi, PhD, Co-Founder, President and CEO of Kymera Therapeutics. Food and Drug Administration (FDA) for its IRAKIMiD degrader, KT-413. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced the clearance of its Investigational New Drug (IND) application from the U.S. WATERTOWN, MA, USA I NovemI Kymera Therapeutics, Inc.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |